Lonza and Hyglos Reach Agreement for Endotoxin Detection Patents
News Mar 15, 2013
Lonza Walkersville, Inc. and Hyglos GmbH have announced that they have reached a mutually beneficial global settlement which includes a license agreement for Hyglos under certain Lonza patents in the area of endotoxin detection.
Specifically, the agreement allows Hyglos to use recombinant factor C technology protected by Lonza’s patents to produce Hyglos’ own endotoxin products.
The agreement also includes the dismissal of the law suit Lonza previously filed against Hyglos.
The terms of the settlement are confidential.
“Thanks to this agreement an important door has opened for a new era in endotoxin detection. We are convinced that Hyglos’ innovative assays, entirely based on recombinant molecules, are addressing important needs of endotoxin testing laboratories worldwide” said Dr. Wolfgang Mutter, General Manager of Hyglos GmbH.
“We are very glad to have reached this agreement with Hyglos. Endotoxin detection using recombinant factor C instead of Limulus amoebocyte lysates has recently been acknowledged by the FDA as an alternative method. We believe that this sustainable animal-free alternative will be the future of endotoxin detection.” concluded Dr. Teun Van der Heide, Head Lonza Bioscience.
BIA Separations appoints Pete Gagnon as Chief Scientific OfficerNews
Appointment will drive new product and applications development.READ MORE
PPD and Quotient Sciences Form Innovative Partnership to Accelerate Pediatric Drug DevelopmentNews
Will shorten timelines, reduce costs and simplify contracting process in pediatric programs.READ MORE
Batavia Biosciences Teams Up with International Consortium to Support Polio EradicationNews
Batavia Biosciences announces its partnership with an international consortium coordinated by PATH aiming to develop and manufacture safer novel oral poliovirus vaccines (nOPV).READ MORE